Connective Issue #9

MIB News
Connective Issue #9

Volume 9 | May 3, 2023 | View in Browser

Beating Cancer is a Team Sport

Collaborating, connecting, and community are so important to us because these are the hallmarks of a winning team, and what we need to beat osteosarcoma together. Scientists, clinicians, patients, caregivers, industry, and donors all play a key role in moving the ball up the field, closer to our goal. We were inspired by the huge team assembled at AACR, all there to tackle cancer from multiple angles. We are incredibly honored to join the NCI MyPART Network team to join forces on finding treatments for rare cancers.  Check out our FACTOR 2023 conference agenda to see the amazing team we've assembled to collaborate on a cure in Atlanta, and our sponsors who make it possible. There are opportunities this month to take advantage of team science funding opportunities from Cancer Grand Challenges and the Samuel Waxman Cancer Research Foundation/Alan B. Slifka Foundation and ICRF. And sometimes a strong team just needs two players, which is the magic of our Ambassador Agents program. Thank you for being part of our team - we are stronger together.

With hope,


Save The Date

Our Community

Check Out the FACTOR Conference Agenda

Join us in advancing treatment for osteosarcoma with six scientific panels and three breakout discussion groups addressing Biomarkers for Risk Stratification, Preclinical Models, Comparative Oncology, Local Control, Immunotherapies, and Molecularly Targeted Therapies.

Register for FACTOR

Book Your Hotel

Finding Hope and Progress at AACR

We were so encouraged by all the exciting work and efforts around the world on Making It Better for osteosarcoma patients at the AACR conference this year. Four mini-symposiums and 60 poster presentations on osteosarcoma!  Treatment and outcomes have not changed in 40 years, but the activity at AACR gives us hope that will change soon.

Read more about AACR 2023

Donate an Auction Item to OutBidding Osteosarcoma

MIB Agents will launch our third annual OutBidding Osteosarcoma auction - live at FACTOR 2023, June 22-24 in Atlanta. Have a unique item or experience that can be auctioned off to the highest bidder? Please complete the donation form by May 15th to join us on our mission to OutBid Osteosarcoma. All funds raised will Make It Better for our Osteosarcoma community.

Donate an Item

Career Connection

If you have a job posting and you would like it included here, please email


OsteoBites Webinar Series

May 4 | Janet Yoon, MD Phase 1 trial with GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2
May 11 | Lee J. Helman, MD and Chelsey Blanks OSI Connect: Osteosarcoma Answers and Assistance
May 18 | osTEAo AYA Podcast Tune in to our AYA podcast to hear OsteoWarriors Camille and Mia discuss finding confidence and identity as an AYA cancer patient.
May 25 | Christian Capitini, MD OSI Connect: Osteosarcoma Answers and Assistance

Watch Past Episodes and See the Upcoming Schedule

Tumor Review Board for Osteosarcoma

A virtual tumor review board for osteosarcoma, TURBO is open to global clinicians or researchers with an interest in osteosarcoma.  Patients and families are welcome to ask their oncologists to present a case on their behalf.  Join TURBO to request an invite or submit a case.

Next meeting: May 10th at 5pm ET


Pediatric Oncology Drug Development Education Portal

ACCELERATE and the 11 members of the ALADDIN consortium have launched a new educational program on strategic and regulatory science in paediatric oncology drug development to foster expertise and strengthen true multi-stakeholder collaboration.

Access the Aladdin Education Portal

Osteosarcoma in the News


Become an Ambassador Agent

The MIB Agents Ambassador Agents program connects osteosarcoma patients and families to the osteosarcoma survivors and their families. Ambassador Agents have walked the osteosarcoma path and are dedicated to providing support and hope to individuals who are in treatment now.

Our next Ambassador Agent training will be held in-person on June 23rd in Atlanta prior to the FACTOR conference. Email to learn more.

Become an Ambassador Agent


MIB Agents Joins the NCI MyPART Network

MIB Agents is honored to join the NCI MyPART Network as an advocacy partner. The MyPART (My Pediatric and Adult Rare Tumor )network is a group of scientists, patients, family members, advocates, and healthcare providers who want to help find treatments for rare cancers like childhood, teen, and young adult solid rare tumors that have no cures. As an advocacy partner, we look forward to working with MyPART to find patients who may want to join MyPART clinics or trials and sharing important information about rare tumors and share resources for patients and their families.

Funding Opportunity Cancer Grand Challenges

Nine of cancer’s toughest challenges with up to $25 million in funding for global research teams. One of the challenges this year: Develop therapeutics to target oncogenic drivers of solid tumours in children. The deadline to apply is 22 June 2023, and shortlisted teams will be announced in August 2023. Expressions of Interest are open until 22 June 2023, with international teams invited to apply for up to $25m in funding.

Apply for Cancer Grand Challenges

Funding Opportunities Pediatric Sarcomas

The Samuel Waxman Cancer Research Foundation (SWCRF), Alan B. Slifka Foundation (ABSF) and Israel Cancer Research Fund (ICRF) have issued a joint Request for Applications (RFA) for collaborative applications focused on fusion-positive pediatric sarcomas. Projects must involve collaboration between two research groups — one in North America and one in Israel — with different but complementary expertise. Proposals must justify the partnership through synergistic scientific aims. One successful collaborative project will be awarded $150,000 per year for two years, or a total of $300,000, with each university-based research group receiving $75,000 per year ($150,000 ). The LOI deadline has been extended to June 1.

Submit LOI by June 1

If you have a trial that is currently enrolling osteosarcoma patients, please email

All MIB Agents programs are free of charge, thanks to our generous donors who Make it Better.


Other blog posts